Last reviewed · How we verify
TRV027 Dose #1
At a glance
| Generic name | TRV027 Dose #1 |
|---|---|
| Also known as | Formerly known as TRV120027 |
| Sponsor | Trevena Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Novel Experimental COVID-19 Therapies Affecting Host Response (PHASE2, PHASE3)
- A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |